134399-26-1

Basic information

• Product Name: 4-benzyloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid
• Synonyms: 4-benzyloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid
• CAS NO: 134399-26-1
• Molecular Weight: 383.232
• Mol File: 134399-26-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-benzyloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-benzyloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid(134399-26-1)
• EPA Substance Registry System: 4-benzyloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid(134399-26-1)

Safety Data

• Hazardous Substances Data: 134399-26-1(Hazardous Substances Data)

Upstream product

• 1885-14-9 phenyl chloroformate 
• 501-53-1 benzyl chloroformate 
• 121268-17-5 sodium alendronate 

Downstream Products

• 134606-39-6 4-benzyloxycarbonylamino-1-hydroxybutylidene-1,1-bisphosphonic acid tri(2,2-dimethylbutanoyloxymethyl) ester 

Relevant articles and documents

Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis

Alendronate derivatives were evaluated as potential prodrugs for the osteoporosis drug alendronate sodium in an attempt to enhance the systemic exposure after oral administration. An investigation of the chemical behavior of alendronate derivatives led to

Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors

The invention relates to acyloxymethyl esters of bisphosphonic acids, halo-bisphosphonic acids and hydroxy-bisphosphonic acids which exhibit oral bioavailability and are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.